ubmslatePT-logo-ubm

PT Mobile Logo

Search form

Topics:

Transplant Psychiatry: Psychiatric Care of Organ Donors and Recipients

Transplant Psychiatry: Psychiatric Care of Organ Donors and Recipients

Table 1 – Psychopharmacology principles in transplant recipientsTable 1 – Psychopharmacology principles in transplant recipients
Commonly used immunosuppressants: mechanisms, psychiatric adverse effectsTable 2 – Commonly used immunosuppressants: mechanisms, psychiatric ad...
Table 3 – Aims of the pre-transplant evaluation of an organ donorTable 3 – Aims of the pre-transplant evaluation of an organ donor

Academy of Psychosomatic Medicine (APM), Transplant Psychiatry Special Interest Group

 

Because of the inherent risks and costs associated with transplant in addition to limited organ availability, careful candidate selection is crucial for successful outcomes. Given the prevalence and effects of psychiatric and substance use disorders on quality of life and post-transplant outcomes, the psychiatrist is often called upon to recommend or implement treatment in both pre-transplant and post-transplant stages.

In Part 1 of this article, the various phases of transplant as well as the prevalence and impact of psychiatric illness in the transplant population were discussed.1 Here we review the psychiatric management of transplant patients and the evaluation and care of living organ donors.

Pre-transplant psychiatric management

It is important that preexisting psychiatric conditions are addressed while patients are being evaluated for or are awaiting transplant. In most cases, the early phase of the pre-transplant stage is an optimal time to “fine-tune” mental health treatment. The underlying medical condition is relatively stable, and the patient can still participate in psychotherapy or receive psychopharmacological treatment.

The hope for better quality of life after transplant can motivate patients to pursue mental health treatments that they had previously refused (eg, start addiction treatment, taper off sedatives, participate in psychotherapy). During this phase, mental health care follows the recommendations available for the psychiatric care of the medically ill.2-4 In addition to general psychosomatic care, specific treatments such as transplant-focused stress-reduction interventions can be useful.5,6 As medical illness worsens, additional challenges may interfere with psychiatric care:

• Patients may become too physically ill to participate in mental health treatment.

• Cognitive impairment may prevent meaningful psychotherapy.

• The logistics of intense medical care (hospitalizations for medical decompensations, high number of medical appointments) may interfere with adherence to psychiatric treatment.

Post-transplant psychiatric management

In the acute post-operative setting, psychiatrists are often asked to help diagnose and manage delirium and steroid-induced psychiatric symptoms. Post-transplant delirium is approached by systematic evaluation of risk factors; addressing acute medical conditions that contribute to delirium (such as infection and metabolic disturbances); simplification of the medication regimen whenever possible (eg, reducing dosages of opioids or benzodiazepines); and behavioral interventions (such as minimizing stimulation, promoting access to daylight normalization of sleep-wake cycle, early mobilization, and frequent reorientation). If medications are used, antipsychotics remain the first line of treatment. Antipsychotics can be safely used to treat delirium or steroid-induced psychosis in the post-transplant phase, while patients are monitored carefully for elevated QTc, seizures, hyponatremia, and neutropenia.

Psychotherapy can be implemented as stand-alone treatment or in addition to pharmacology.

In the long term, several studies have documented that depression or psychosis in the post-transplant phase is associated with worse medical outcomes.7,8 For substance use disorder, findings suggest that post-transplant treatment is as important as pre-transplant relapse prevention in helping patients maintain abstinence.9 General considerations regarding pharmacological treatment of organ transplant recipients are outlined in Table 1. The life-long immunosuppressant regimen may lead to psychiatric symptoms, pharmacokinetic interactions with psychiatric medications, or synergistic effects that can alter long-term outcomes (Table 2).

Psychotherapy can be implemented as stand-alone treatment or in addition to pharmacology, provided there is no significant cognitive impairment. Relevant themes for psychotherapy in the post-transplant setting are loss (of time spent ill waiting for an organ, of social status, financial situation); change in social role (from critically ill to quasi-healthy); acceptance of the post-transplant limitations because of medical comorbidities not improved with the transplant (eg, diabetic retinopathy after a kidney transplant); guilt; body image concerns; living with an increased risk of health problems (malignancies, infections); medication adherence; and expressing gratitude toward the donor or his or her family. Many transplantation centers offer counseling focused on improving medication adherence and communicating with the donor or the donor’s family.

Pages

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.